Skip to main content

Formation of stable nanocarriers by in Situ ion pairing during block-copolymer-directed rapid precipitation

Author(s): Pinkerton, NM; Grandeury, A; Fisch, A; Brozio, J; Riebesehl, BU; et al

Download
To refer to this page use: http://arks.princeton.edu/ark:/88435/pr1cr4h
Abstract: We present an in situ hydrophobic salt forming technique for the encapsulation of weakly hydrophobic, ionizable active pharmaceutical ingredients (API) into stable nanocarriers (NCs) formed via a rapid precipitation process. Traditionally, NC formation via rapid precipitation has been difficult with APIs in this class because their intermediate solubility makes achieving high supersaturation difficult during the precipitation process and the intermediate solubility causes rapid Ostwald ripening or recrystallization after precipitation. By forming a hydrophobic salt in situ, the API solubility and crystallinity can be tuned to allow for NC formation. Unlike covalent API modification, the hydrophobic salt formation modifies properties via ionic interactions, thus circumventing the need for full FDA reapproval. This technique greatly expands the types of APIs that can be successfully encapsulated in NC form. Three model APIs were investigated and successfully incorporated into NCs by forming salts with hydrophobic counterions: cinnarizine, an antihistamine, clozapine, an antipsychotic, and α-lipoic acid, a common food supplement. We focus on cinnarizine to develop the rules for the in situ nanoprecipitation of salt NCs. These rules include the pK as and solubilities of the API and counterion, the effect of the salt former-to-API ratio on particle stability and encapsulation efficiency, and the control of NC size. Finally, we present results on the release rates of these ion pair APIs from the NCs.
Publication Date: 2013
Citation: Pinkerton, NM, Grandeury, A, Fisch, A, Brozio, J, Riebesehl, BU, Prud Homme, RK. (2013). Formation of stable nanocarriers by in Situ ion pairing during block-copolymer-directed rapid precipitation. Molecular Pharmaceutics, 10 (319 - 328. doi:10.1021/mp300452g
DOI: doi:10.1021/mp300452g
Pages: 319 - 328
Type of Material: Journal Article
Journal/Proceeding Title: Molecular Pharmaceutics
Version: Author's manuscript



Items in OAR@Princeton are protected by copyright, with all rights reserved, unless otherwise indicated.